German pharmaceutical company BioNTech was back in profit in the third quarter of 2024, it announced on Monday, with comparatively early approvals for adapted coronavirus vaccines driving up sales.

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...

Pfizer and BioNTech have been among the leaders in the race to bring a combined COVID-19 and influenza vaccine to market, but have stumbled in the final straight. The companies reported mixed ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy than ...

Most countries reported data for all three influenza seasons between 2021–22 and 2023 ... were the Comirnaty Omicron XBB.1.5 (Pfizer BioNTech) vaccine. Around 687 529 doses (2.2% of the total doses ...

This is akin to a strain change for a seasonal influenza vaccine. For the Pfizer/BioNTech and Moderna vaccines, this means that small changes were made to the mRNA in the vaccine so that the ...

This is akin to a strain change for a seasonal influenza vaccine. For the Pfizer/BioNTech and Moderna vaccines, this means that small changes were made to the mRNA in the vaccine so that the ...